device developed specifically for the treatment for aortic regurgitation has met all the prespecified safety and efficacy goals, so far, in an expansion cohort of the ALIGN-AR trial, paving the ...

with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's prespecified goal of 25% to show non-inferiority, according to a ...